Orlipastat 96829-58-2 Anabolic Weight loss Medicine Orlistat for Fat Burning


Quick Details :

1. Product Name: Orlistat
2. Synonyms : (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S, 3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER; RO-18-0647
3. CAS NO: 96829-58-2
4. MF: C29H53NO5
5. MW: 495.73
6. Storage temp: 2-8°C
7. Color : white
8. Solubility : DMSO: 19 mg/mL
9. Product Categories: Pharmaceutical Raw Materials; Miscellaneous Biochemicals; API; Antiobesity Agent; Chiral Reagents; Intermediates & Fine Chemicals; Pharmaceuticals; Amino Acids & Derivatives; Heterocycles; ACTOS; Other APIs; Lipid-lowering medicine reducing weight
10. Appearance: Off-White Solid
11. Grade : Pharmaceutical Grade
12. Brand Name: NJBN STEROID
13. Purity: > 99%
14. Usage : Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.

Description:

1. Orlistat is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States. Its primary function is preventing the absorption of fats from the human diet by acting as alipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

2. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.

3. The effectiveness of orlistat in promoting weight loss is definite but modest. Pooled data from clinical trialssuggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2-3 kilograms (4.4-6.6 lb) more than those not taking the drug over the course of a year. Orlistat also modestly reduces blood pressure and appears to prevent the onset of type 2 diabetes, whether from the weight loss itself or to other effects. In a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

4. Benefits aside, however, orlistat is notorious for its gastrointestinal side effects (sometimes referred to astreatment effects), which can include steatorrhea (oily, loose stools). They decrease with time, however, and are the most frequently reported adverse effects of the the United States and the European Union, orlistat is available for sale without a prescription. Over-the-counter approval was controversial in the United States, with consumer advocacy group Public Citizen repeatedly opposing it on safety and efficacy grounds. Genericformulations of orlistat are available in some countries. In Australia it is listed as an S3 medication and so is available over the counter in pharmacies.

Application :

1. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
2. Orlistat is a drug that promotes loss of weight by preventing the digestionand absorption of fat in food. In the intestine, an enzyme called lipase (produced primarily by the pancreas) breaks apart fat in food so that it can be absorbed into the body. Orlistat blocks the action of lipase and thereby prevents the breakup and absorption of fat. Orlistat blocks absorption of about 25% of the fat in a meal. The unabsorbed fat is excreted in the stool. The FDA approved Orlistat by prescription in 1999. Alli, a lower dose formulation of orlistat, was approved for purchase without a prescription "over the counter" in 2007.

Hi, I'm teresa, everybody is taking the similar words, what I want to say is: Just give me a chance, Just have a try on me, maybe you will get a big surprise on me, come to join us, Buddy!